FILSPARI holds strong market potential as the first FDA-approved non-immunosuppressive therapy for IgA nephropathy, a rare kidney disease with significant unmet needs. As more patients and providers ...

IgAN is an autoimmune disease that occurs when an antibody known as immunoglobulin A (IgA) is deposited in the kidney in clumps. This can damage the kidneys and cause inflammation. IgAN is a ...

In the long battle to create an effective HIV vaccine, scientists have made a major leap forward. A new study shows that a ...

Panelists discuss how disease-modifying therapies for immunoglobulin A (IgA) nephropathy, though initially more expensive ...

Scientists have created a new type of super-strong antibody that could significantly enhance cancer immunotherapy. In an ...

CSL Vifor is pleased to announce that the National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending that sparsentan can be used in the NHS in England as ...

Sparsentan is expected to be funded in England by 27 June 2025, within 90 days of the final guidance publication. IgA ...

Iga Swiatek arrives at Roland Garros in a moment of doubt, but it could be the ideal stage to give her season a boost and win a title again. For now, the Pole has four titles at the French Open ...

Symptoms manifest themselves in the kidney, as function progressively deteriorates as the organ becomes inflamed as a result of lodged IgA antibody complexes. These IgA antibodies are actually ...